Multicenter Phase II Trial of Temsirolimus (TEM) and Bevacizumab (BEV) in Pancreatic Neuroendocrine Tumor (PNET).
Journal of Clinical Oncology - United States
doi 10.1200/jco.2012.30.4_suppl.260
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2012
Authors
Publisher
American Society of Clinical Oncology (ASCO)